Literature DB >> 31720935

KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.

Qiongyan Zhang1,2,3, Junjie Peng2,4, Min Ye1,2, Weiwei Weng1,2, Cong Tan1,2, Shujuan Ni1,2, Dan Huang1,2, Weiqi Sheng5,6, Lei Wang7,8.   

Abstract

BACKGROUND: The presence of micrometastases is a source of recurrence after surgical resection of colorectal liver metastases (CRLM). The KRAS mutation is common in colorectal cancer, however the correlation between KRAS status and micrometastases has not been thoroughly clarified.
METHODS: We enrolled a cohort of 251 consecutive CRLM patients who received complete liver surgery with known KRAS mutation status, and collected clinicopathological information, including micrometastases, margin status, preoperative chemotherapy, and liver recurrence-free survival (LRFS) and overall survival (OS) rates.
RESULTS: KRAS-mutant (mutKRAS) patients had a higher incidence (60.3 vs. 40.8%; p = 0.002) and higher number of micrometastases [2.0 (range 0-38.0) vs. 0 (range 0-15.0); p < 0.001] than KRAS wild-type (wtKRAS) patients. The micrometastases in the mutKRAS group were more distant than those in the wtKRAS group [0.7 (range 0.1-9.0) vs. 0.6 (range 0.2-5.0) mm; p = 0.018). The mutKRAS group had more involved margin resections (21.5 vs. 9.2%; p = 0.07) and narrower margin widths [2.0 (range 0-40.0) vs. 4.3 (0-50.0) mm; p = 0.002] than the wtKRAS group. In addition, preoperative chemotherapy was associated with a lower rate of micrometastases in mutKRAS CRLM tumors (p < 0.05). mutKRAS status, positive margins, and micrometastases were all related to worse LRFS and OS (p < 0.05); however, micrometastases were not significantly correlated with OS in the multivariate analysis (p = 0.106).
CONCLUSIONS: mutKRAS patients had more micrometastases, increased R1 resections, and narrower margins. The presence of micrometastases may have led to the narrow margin width observed in these cases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31720935     DOI: 10.1245/s10434-019-08065-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E Van Cutsem; A Cervantes; B Nordlinger; D Arnold
Journal:  Ann Oncol       Date:  2014-09-04       Impact factor: 32.976

2.  Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Hitoshi Kameyama; Hitoshi Nogami; Tsuneo Iiai; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  Int J Clin Exp Pathol       Date:  2012-04-16
  2 in total
  5 in total

1.  Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.

Authors:  Nozomu Sakai; Katsunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Shigetsugu Takano; Masayuki Ohtsuka
Journal:  BMC Cancer       Date:  2021-04-15       Impact factor: 4.430

Review 2.  Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases.

Authors:  Rami Rhaiem; Linda Rached; Ahmad Tashkandi; Olivier Bouché; Reza Kianmanesh
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

3.  Gene Alterations, Mediators, and Artificial Intelligence in Colorectal Liver Metastases.

Authors:  Doris Wagner; Georgios Antonios Margonis
Journal:  Cells       Date:  2022-07-15       Impact factor: 7.666

Review 4.  The Role of Biomarkers in the Management of Colorectal Liver Metastases.

Authors:  Daniel Brock Hewitt; Zachary J Brown; Timothy M Pawlik
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

Review 5.  Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?

Authors:  Markus K Diener; Stefan Fichtner-Feigl
Journal:  Ann Gastroenterol Surg       Date:  2021-07-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.